医学
神经学
药品
临床试验
免疫学
免疫系统
抗体
计算生物学
多发性硬化
疾病
重症监护医学
神经科学
临床神经学
作者
Tobias Ruck,Falk Nimmerjahn,Heinz Wiendl,Jan D Lünemann
出处
期刊:Brain
[Oxford University Press]
日期:2021-12-20
卷期号:145 (4): 1229-1241
被引量:1
标识
DOI:10.1093/brain/awab465
摘要
Antibody-based therapeutics are now standard in the treatment of neuroinflammatory diseases, and the spectrum of neurological diseases targeted by those approaches continues to grow. The efficacy of antibody-based drug platforms is largely determined by the specificity-conferring antigen-binding fragment (Fab) and the crystallizable fragment (Fc) driving antibody function. The latter provides specific instructions to the immune system by interacting with cellular Fc receptors and complement components. Extensive engineering efforts have enabled tuning of Fc functions to modulate effector functions and to prolong or reduce antibody serum half-lives. Technologies that improve bioavailability of antibody-based treatment platforms within the CNS parenchyma are being developed and could invigorate drug discovery for a number of brain diseases for which current therapeutic options are limited. These powerful approaches are currently being tested in clinical trials or have been successfully translated into the clinic. Here, we review recent developments in the design and implementation of antibody-based treatment modalities in neurological diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI